India: Healthcare

The Hon’ble Delhi High Court has granted a permanent injunction in favour of the American pharmaceutical and medical devices giant Johnson & Johnson (“J&J”), restraining a New Delhi-based entity from infringing its trademarks ‘Surgicel’, ‘Ligaclip’ and ‘Ethicon’, and from manufacturing, distributing, or selling counterfeit surgical devices. Recognising the grave public health risks posed by counterfeit medical products, the Court also awarded damages amounting to approximately ₹3.34 crore against the defendants.

India's pharmaceutical patent system navigates the delicate balance between protecting innovation and ensuring affordable access to life-saving medicines for millions living in poverty. Through mechanisms like compulsory licensing and restrictions on patent evergreening, the country attempts to honor its TRIPS obligations while maintaining its role as the "Pharmacy of the World." How effectively do these legal safeguards reconcile the competing interests of global pharmaceutical giants and public health nee

The Delhi High Court in Medilabo RFP Inc. v. Controller of Patents[1] set aside a refusal under Section 3(i) of the Patents Act, 1970 concerning a pharmaceutical invention for neurodegenerative diseases, The Court’s intervention turned on a more fundamental principle of patent adjudication: the Controller must decide an application on the basis of the claims as they stand on the date of the order and must deal with every objection raised in the hearing notice through reasoned findings.

Explore comprehensive analyses of recent Indian tax rulings, FDI policy updates, and international trade agreements. From transfer pricing safe harbour rules to the India-New Zealand FTA, discover how regulatory changes impact cross-border transactions, foreign investment, and corporate tax compliance.

In a significant exercise of delegated legislative authority, the Ministry of Labour and Employment, Government of India, issued Notification S.O. 2352(E) on the 8th of May 2026.

The importance of these decisions lies in their widespread impact. Countries like Brazil and South Africa have implemented India's approach in their own healthcare challenges. Fundamentally, this issue extends beyond patents, touching on the principles of fairness, dignity, and justice in the realm of global health.

The interplay between complex medical conditions and rigid statutory definitions frequently poses profound challenges to the adjudication of fundamental rights.

The global medical device industry is undergoing remarkable expansion, driven by technological innovation, rising healthcare demands, and increased investment across markets.

India's care economy sector stands at a transformative juncture, driven by rapid demographic aging and Budget 2026-27's landmark policy interventions.